EXTENDICARE INC (EXE.CA) Fundamental Analysis & Valuation

TSX:EXE • CA30224T8639

Current stock price

29.56 CAD
+0.13 (+0.44%)
Last:

This EXE.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. EXE.CA Profitability Analysis

1.1 Basic Checks

  • In the past year EXE was profitable.
  • EXE had a positive operating cash flow in the past year.
  • EXE had positive earnings in each of the past 5 years.
  • In the past 5 years EXE always reported a positive cash flow from operatings.
EXE.CA Yearly Net Income VS EBIT VS OCF VS FCFEXE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M 150M

1.2 Ratios

  • EXE has a Return On Assets of 9.06%. This is amongst the best in the industry. EXE outperforms 92.31% of its industry peers.
  • EXE's Return On Equity of 25.89% is amongst the best of the industry. EXE outperforms 92.31% of its industry peers.
  • With an excellent Return On Invested Capital value of 14.09%, EXE belongs to the best of the industry, outperforming 92.31% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for EXE is significantly above the industry average of 6.93%.
Industry RankSector Rank
ROA 9.06%
ROE 25.89%
ROIC 14.09%
ROA(3y)8.19%
ROA(5y)6.95%
ROE(3y)41.67%
ROE(5y)41.08%
ROIC(3y)14.71%
ROIC(5y)10.79%
EXE.CA Yearly ROA, ROE, ROICEXE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

1.3 Margins

  • The Profit Margin of EXE (5.82%) is better than 84.62% of its industry peers.
  • EXE's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 8.35%, EXE is in the better half of the industry, outperforming 76.92% of the companies in the same industry.
  • EXE's Operating Margin has been stable in the last couple of years.
  • The Gross Margin of EXE (14.26%) is worse than 84.62% of its industry peers.
  • In the last couple of years the Gross Margin of EXE has declined.
Industry RankSector Rank
OM 8.35%
PM (TTM) 5.82%
GM 14.26%
OM growth 3Y57.94%
OM growth 5Y0.49%
PM growth 3Y0.74%
PM growth 5Y4.46%
GM growth 3Y17.09%
GM growth 5Y-1.93%
EXE.CA Yearly Profit, Operating, Gross MarginsEXE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

7

2. EXE.CA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXE is creating value.
  • EXE has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, EXE has more shares outstanding
  • EXE has a better debt/assets ratio than last year.
EXE.CA Yearly Shares OutstandingEXE.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
EXE.CA Yearly Total Debt VS Total AssetsEXE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 4.15 indicates that EXE is not in any danger for bankruptcy at the moment.
  • EXE has a Altman-Z score of 4.15. This is amongst the best in the industry. EXE outperforms 84.62% of its industry peers.
  • EXE has a debt to FCF ratio of 3.18. This is a good value and a sign of high solvency as EXE would need 3.18 years to pay back of all of its debts.
  • EXE has a better Debt to FCF ratio (3.18) than 84.62% of its industry peers.
  • EXE has a Debt/Equity ratio of 0.83. This is a neutral value indicating EXE is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.83, EXE is in line with its industry, outperforming 53.85% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF 3.18
Altman-Z 4.15
ROIC/WACC1.86
WACC7.58%
EXE.CA Yearly LT Debt VS Equity VS FCFEXE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.37 indicates that EXE should not have too much problems paying its short term obligations.
  • EXE has a better Current ratio (1.37) than 92.31% of its industry peers.
  • EXE has a Quick Ratio of 1.37. This is a normal value and indicates that EXE is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of EXE (1.37) is better than 92.31% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.37
EXE.CA Yearly Current Assets VS Current LiabilitesEXE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

6

3. EXE.CA Growth Analysis

3.1 Past

  • EXE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.99%, which is quite impressive.
  • The Earnings Per Share has been growing by 15.56% on average over the past years. This is quite good.
  • The Revenue has grown by 13.25% in the past year. This is quite good.
  • Measured over the past years, EXE shows a small growth in Revenue. The Revenue has been growing by 7.47% on average per year.
EPS 1Y (TTM)40.99%
EPS 3Y12.58%
EPS 5Y15.56%
EPS Q2Q%34.86%
Revenue 1Y (TTM)13.25%
Revenue growth 3Y10.77%
Revenue growth 5Y7.47%
Sales Q2Q%18%

3.2 Future

  • EXE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.95% yearly.
  • Based on estimates for the next years, EXE will show a quite strong growth in Revenue. The Revenue will grow by 13.52% on average per year.
EPS Next Y16.31%
EPS Next 2Y16.61%
EPS Next 3Y15.95%
EPS Next 5YN/A
Revenue Next Year32.28%
Revenue Next 2Y19.54%
Revenue Next 3Y13.52%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EXE.CA Yearly Revenue VS EstimatesEXE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B 2B
EXE.CA Yearly EPS VS EstimatesEXE.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5

4

4. EXE.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 26.63 indicates a quite expensive valuation of EXE.
  • 76.92% of the companies in the same industry are more expensive than EXE, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 27.38, EXE is valued at the same level.
  • A Price/Forward Earnings ratio of 24.14 indicates a rather expensive valuation of EXE.
  • EXE's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. EXE is cheaper than 76.92% of the companies in the same industry.
  • EXE is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 38.20, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 26.63
Fwd PE 24.14
EXE.CA Price Earnings VS Forward Price EarningsEXE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

  • EXE's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. EXE is cheaper than 69.23% of the companies in the same industry.
  • EXE's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 26.93
EV/EBITDA 15.8
EXE.CA Per share dataEXE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of EXE may justify a higher PE ratio.
  • EXE's earnings are expected to grow with 15.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.63
PEG (5Y)1.71
EPS Next 2Y16.61%
EPS Next 3Y15.95%

5

5. EXE.CA Dividend Analysis

5.1 Amount

  • EXE has a Yearly Dividend Yield of 1.79%.
  • Compared to an average industry Dividend Yield of 1.37, EXE pays a bit more dividend than its industry peers.
  • EXE's Dividend Yield is comparable with the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.79%

5.2 History

  • The dividend of EXE has a limited annual growth rate of 0.28%.
  • EXE has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)0.28%
Div Incr Years0
Div Non Decr Years0
EXE.CA Yearly Dividends per shareEXE.CA Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.1 0.2 0.3 0.4 0.5

5.3 Sustainability

  • EXE pays out 43.14% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • The dividend of EXE is growing, but earnings are growing more, so the dividend growth is sustainable.
DP43.14%
EPS Next 2Y16.61%
EPS Next 3Y15.95%
EXE.CA Yearly Income VS Free CF VS DividendEXE.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M
EXE.CA Dividend Payout.EXE.CA Dividend Payout, showing the Payout Ratio.EXE.CA Dividend Payout.PayoutRetained Earnings

EXE.CA Fundamentals: All Metrics, Ratios and Statistics

EXTENDICARE INC

TSX:EXE (4/14/2026, 7:00:00 PM)

29.56

+0.13 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners24.54%
Inst Owner ChangeN/A
Ins Owners1.19%
Ins Owner ChangeN/A
Market Cap2.79B
Revenue(TTM)1.66B
Net Income(TTM)96.66M
Analysts78
Price Target31 (4.87%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.79%
Yearly Dividend0.47
Dividend Growth(5Y)0.28%
DP43.14%
Div Incr Years0
Div Non Decr Years0
Ex-Date03-31
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)26.9%
PT rev (3m)26.83%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)7.3%
EPS NY rev (3m)3.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.85%
Revenue NY rev (3m)-2.89%
Valuation
Industry RankSector Rank
PE 26.63
Fwd PE 24.14
P/S 1.68
P/FCF 26.93
P/OCF 17.07
P/B 7.48
P/tB 15.68
EV/EBITDA 15.8
EPS(TTM)1.11
EY3.76%
EPS(NY)1.22
Fwd EY4.14%
FCF(TTM)1.1
FCFY3.71%
OCF(TTM)1.73
OCFY5.86%
SpS17.58
BVpS3.95
TBVpS1.89
PEG (NY)1.63
PEG (5Y)1.71
Graham Number9.9357 (-66.39%)
Profitability
Industry RankSector Rank
ROA 9.06%
ROE 25.89%
ROCE 18.83%
ROIC 14.09%
ROICexc 26.71%
ROICexgc 53.72%
OM 8.35%
PM (TTM) 5.82%
GM 14.26%
FCFM 6.24%
ROA(3y)8.19%
ROA(5y)6.95%
ROE(3y)41.67%
ROE(5y)41.08%
ROIC(3y)14.71%
ROIC(5y)10.79%
ROICexc(3y)22.22%
ROICexc(5y)15.92%
ROICexgc(3y)39.32%
ROICexgc(5y)26.96%
ROCE(3y)19.66%
ROCE(5y)14.43%
ROICexgc growth 3Y88.69%
ROICexgc growth 5Y25.88%
ROICexc growth 3Y67.25%
ROICexc growth 5Y13.75%
OM growth 3Y57.94%
OM growth 5Y0.49%
PM growth 3Y0.74%
PM growth 5Y4.46%
GM growth 3Y17.09%
GM growth 5Y-1.93%
F-Score6
Asset Turnover1.56
Health
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF 3.18
Debt/EBITDA 1.77
Cap/Depr 162.15%
Cap/Sales 3.61%
Interest Coverage 12.73
Cash Conversion 93.15%
Profit Quality 107.28%
Current Ratio 1.37
Quick Ratio 1.37
Altman-Z 4.15
F-Score6
WACC7.58%
ROIC/WACC1.86
Cap/Depr(3y)229.86%
Cap/Depr(5y)237.24%
Cap/Sales(3y)5.46%
Cap/Sales(5y)6.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.99%
EPS 3Y12.58%
EPS 5Y15.56%
EPS Q2Q%34.86%
EPS Next Y16.31%
EPS Next 2Y16.61%
EPS Next 3Y15.95%
EPS Next 5YN/A
Revenue 1Y (TTM)13.25%
Revenue growth 3Y10.77%
Revenue growth 5Y7.47%
Sales Q2Q%18%
Revenue Next Year32.28%
Revenue Next 2Y19.54%
Revenue Next 3Y13.52%
Revenue Next 5YN/A
EBIT growth 1Y24.69%
EBIT growth 3Y74.95%
EBIT growth 5Y7.99%
EBIT Next Year53.59%
EBIT Next 3Y21.49%
EBIT Next 5YN/A
FCF growth 1Y1.97%
FCF growth 3YN/A
FCF growth 5Y3.29%
OCF growth 1Y13.89%
OCF growth 3Y18.28%
OCF growth 5Y6.16%

EXTENDICARE INC / EXE.CA Fundamental Analysis FAQ

What is the fundamental rating for EXE stock?

ChartMill assigns a fundamental rating of 6 / 10 to EXE.CA.


What is the valuation status for EXE stock?

ChartMill assigns a valuation rating of 4 / 10 to EXTENDICARE INC (EXE.CA). This can be considered as Fairly Valued.


How profitable is EXTENDICARE INC (EXE.CA) stock?

EXTENDICARE INC (EXE.CA) has a profitability rating of 7 / 10.


What is the valuation of EXTENDICARE INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for EXTENDICARE INC (EXE.CA) is 26.63 and the Price/Book (PB) ratio is 7.48.


How financially healthy is EXTENDICARE INC?

The financial health rating of EXTENDICARE INC (EXE.CA) is 7 / 10.